ARTICLE | Company News
Sinclair, Anabiosis Ltd., Chester Valley sales and marketing update
August 1, 2005 7:00 AM UTC
SPH granted Chester Valley U.S. market rights to Sebclair to treat seborrheic dermatitis. SPH could receive $4 million in upfront and milestone payments, plus royalties. Chester Valley already has U.S. marketing rights to SPH's Atopiclair device for atopic and allergic dermatitis. ...